Article

EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes

Gastroenterology Division, Department of Medicine, Abramson Cancer Center and Family Cancer Research Institute, University of Pennsylvania, 415 Curie Blvd., Philadelphia, PA 19104, USA.
AJP Gastrointestinal and Liver Physiology (Impact Factor: 3.8). 01/2005; 287(6):G1227-37. DOI: 10.1152/ajpgi.00253.2004
Source: PubMed

ABSTRACT

The epidermal growth factor receptor (EGFR) activates several signaling cascades in response to epidermal growth factor stimulation. One of these signaling events involves tyrosine phosphorylation of signal transducer and activator of transcription (STAT), whereas another involves activation of the phosphatidylinositol 3-OH kinase pathway. Two possibilities for STAT activation exist: a janus kinase (JAK)-dependent and a JAK-independent mechanism. Herein, we demonstrate that EGFR overexpression in primary esophageal keratinocytes activates STAT in a JAK-dependent fashion with the functional consequence of enhanced cell migration, which can be abolished by use of a JAK-specific inhibitor, AG-490. We determined the mechanisms underlying the signal transduction pathway responsible for increased cell migration. Stimulation of EGFR induces Tyr701 phosphorylation of STAT1 and initiates complex formation of STAT1 and STAT3 with JAK1 and JAK2. Thereafter, the STATs translocate to the nucleus within 15 min. In addition, we found that activation of this signaling pathway results in matrix metalloproteinase-1 (MMP-1) activity. By contrast, Akt activation does not impact the EGFR-STATs-JAKs complex formation and nuclear translocation of the STATs with subsequent MMP-1 activity, although Akt activation may contribute to cell migration through an independent mechanism. Taken together, we find that the recruitment of the STAT-JAK complex by EGFR is responsible for keratinocyte migration that, in turn, might be mediated by MMP-1 activation.

Download full-text

Full-text

Available from: Claudia Andl
  • Source
    • "Furthermore, one of the signaling events implicates tyrosine phosphorylation and activation of STAT3 protein [82]. This is in line with the previous demonstration that EGFR-induced cell migration is mediated predominantly by the STAT-pathway in keratinocytes and that STAT3 plays an essential role for skin remodeling and wound healing [82,83]. Esculentin-1a(1-21)NH 2 Stimulates Migration of Keratinocytes PLOS ONE | DOI:10.1371/journal.pone.0128663 "
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the many functions of skin is to protect the organism against a wide range of pathogens. Antimicrobial peptides (AMPs) produced by the skin epithelium provide an effective chemical shield against microbial pathogens. However, whereas antibacterial/antifungal activities of AMPs have been extensively characterized, much less is known regarding their wound healing-modulatory properties. By using an in vitro re-epithelialisation assay employing special cell-culture inserts, we detected that a derivative of the frog-skin AMP esculentin-1a, named esculentin-1a(1-21)NH2, significantly stimulates migration of immortalized human keratinocytes (HaCaT cells) over a wide range of peptide concentrations (0.025-4 μM), and this notably more efficiently than human cathelicidin (LL-37). This activity is preserved in primary human epidermal keratinocytes. By using appropriate inhibitors and an enzyme-linked immunosorbent assay we found that the peptide-induced cell migration involves activation of the epidermal growth factor receptor and STAT3 protein. These results suggest that esculentin-1a(1-21)NH2 now deserves to be tested in standard wound healing assays as a novel candidate promoter of skin re-epithelialisation. The established ability of esculentin-1a(1-21)NH2 to kill microbes without harming mammalian cells, namely its high anti-Pseudomonal activity, makes this AMP a particularly attractive candidate wound healing promoter, especially in the management of chronic, often Pseudomonas-infected, skin ulcers.
    Full-text · Article · Jun 2015 · PLoS ONE
  • Source
    • "Stimulation of ErbB3 receptors with its ligand HRG activates Rac1 through transactivation of EGFR, as pharmacological inhibition or RNAi depletion of EGFR significantly reduces Rac1-dependent motility (Yang et al., 2006). As there is considerable evidence that EGFR-mediated responses involve the Jak2/Stat3 pathway in various cancer cell models (Yamauchi et al., 1997; Liu and Kern, 2002; Andl et al., 2004; Lo et al., 2008; Yang et al., 2008; Coaxum et al., 2009; Colomiere et al., 2009), we decided to examine whether Jak2 was implicated in Rac1 activation by HRG. To address this issue, we used the Jak2 inhibitor cucurbitacin I, which is known to inhibit Jak2/Stat3 with an IC 50 in the high nanomolar range (Blaskovich et al., 2003; Chen et al., 2005; Iwanski et al., 2010; Lee et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-GEF P-Rex1. As the Jak2/Stat3 pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNAi, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector ROCK in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-Acetyl L-cysteine (NAC) and the mitochondrial anti-oxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac.
    Full-text · Article · Mar 2013 · Molecular pharmacology
  • Source
    • "Interestingly, only one metastatic tumour sample (MET_HR_10) shows strong loss of expression of ERBB2 (HER2), a gene often associated with promoting cell proliferation, particularly in breast cancer [47,48]. It is known, however, that loss of expression of ERBB2 is a feature of metastatic sites in breast cancer that is otherwise ERBB2 positive [49] and further that loss of ERBB2 expression has been strongly associated with progression to metastasis in osteosarcoma [50]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Cancer outlier profile analysis (COPA) has proven to be an effective approach to analyzing cancer expression data, leading to the discovery of the TMPRSS2 and ETS family gene fusion events in prostate cancer. However, the original COPA algorithm did not identify down-regulated outliers, and the currently available R package implementing the method is similarly restricted to the analysis of over-expressed outliers. Here we present a modified outlier detection method, mCOPA, which contains refinements to the outlier-detection algorithm, identifies both over- and under-expressed outliers, is freely available, and can be applied to any expression dataset. Results We compare our method to other feature-selection approaches, and demonstrate that mCOPA frequently selects more-informative features than do differential expression or variance-based feature selection approaches, and is able to recover observed clinical subtypes more consistently. We demonstrate the application of mCOPA to prostate cancer expression data, and explore the use of outliers in clustering, pathway analysis, and the identification of tumour suppressors. We analyse the under-expressed outliers to identify known and novel prostate cancer tumour suppressor genes, validating these against data in Oncomine and the Cancer Gene Index. We also demonstrate how a combination of outlier analysis and pathway analysis can identify molecular mechanisms disrupted in individual tumours. Conclusions We demonstrate that mCOPA offers advantages, compared to differential expression or variance, in selecting outlier features, and that the features so selected are better able to assign samples to clinically annotated subtypes. Further, we show that the biology explored by outlier analysis differs from that uncovered in differential expression or variance analysis. mCOPA is an important new tool for the exploration of cancer datasets and the discovery of new cancer subtypes, and can be combined with pathway and functional analysis approaches to discover mechanisms underpinning heterogeneity in cancers.
    Full-text · Article · Dec 2012 · Journal of Clinical Bioinformatics
Show more